Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (1282)	3/21/1998 12:36:00 AM
From: hb	Respond to of 2173

Suggestions to the company: 1. They ought to enter in countries like India (where vegetarians eat lots of carbo)where diabetes is a major issue.2. If the drug lowers weight, that is a plus for diabetic patient (and for heart);3. As long as there is no side effect, it is worth it if successful in 25% of the diabetics. 4. Based on the experience with big drug companies who do not like to have their current products' importance be diminished due to a new drug, JNJ action is suspecious.(e.g.,for stomach ulcers antibacterial medication is the cure in 95% cases, but are always treated with a temporary solution of antacid formulations. this is because antacid is multibillion dollar market)